This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
== Circular economy == Recent research has begun to investigate the relationship between fermentation and creating a circular economy in effort to address the current climate crisis and the increasing demands for resources as the population grows. The production of fuels, materials, and other chemicals has led to a notable increase in greenhouse gasses and a subsequent increase in global temperatures. The current, linear economy relies heavily on fossil fuels and nonrenewable energy to produce chemicals and materials. In a circular economy, the use of renewable resources would be employed to produce chemicals; moreover, this type of economy focuses on reusing end-of-life chemicals and materials. Investigation into alternative biofuels and biomaterials has become increasingly popular with fermentation as a notable method. The primary source of biomass for fermentation is using biomass feedstocks which contain a mix of carbohydrates, proteins, oils and fats, and lignin. Carbohydrates such as sucrose and starch (sources include sugarcane, corn, and cassava) are the most commonly used substrate for fermentation; however, in the discussion of biofuels, there are concerns regarding land competition between food and fuel biomass. Attention has been turned towards second-generation biomass feedstock such as silvergrass or wood chips.
The Bowery Mural is an outdoor exhibition space located on the corner of Houston Street and the Bowery, on a wall owned by Goldman Properties since 1984. Real estate developer Tony Goldman began the project with Jeffery Deitch and Deitch Projects in 2008. Goldman's goal was to use this wall to present the top contemporary artists from around the world, with an emphasis on artists who work on the streets. Seasonal murals have appeared on the wall curated and organized in collaboration with The Hole, NYC, an art gallery in SoHo run by former Deitch Projects directors Kathy Grayson and Meghan Coleman. The mural series was initiated from March to December 2008 with a tribute to Keith Haring’s noted 1982 Bowery mural. This was followed by a mural by the Brazilian twin-brother duo Os Gêmeos, which they dedicated to artist Dash Snow, who had recently died from a drug overdose; this was presented from July 2009 to March 2010. The next mural, by Shepard Fairey, was on exhibit from April through August 2010, and was followed by a mural by Barry McGee which celebrated the role of graffiti tagging in the history of New York City street art; it was on display from August to November 2010. This was followed by a tribute to Dash Snow by Irak, which ran from November 24–26, 2010. Other artists to have murals presented include the twins How & Nosm (2012), Crash (2013), Martha Cooper (2013), Revok and Pose (2013), Swoon (2014), and Maya Hayuk.
The three substrates of this enzyme are L-phenylalanine, water, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are phenylpyruvic acid, ammonia, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-phenylalanine:NAD+ oxidoreductase (deaminating). Other names in common use include L-phenylalanine dehydrogenase, and PHD. This enzyme participates in phenylalanine metabolism and phenylalanine, tyrosine and tryptophan biosynthesis.
==== Radiation Damping ==== In 1949, Suryan first suggested that the interaction between a radiofrequency coil and a sample's bulk magnetization could explain why experimental observations of relaxation times differed from theoretical predictions. Building on this idea, Bloembergen and Pound further developed Suryan's hypothesis by mathematically integrating the Maxwell–Bloch equations, a process through which they introduced the concept of "radiation damping." Radiation damping (RD) in Nuclear Magnetic Resonance (NMR) is an intrinsic phenomenon observed in many high-field NMR experiments, especially relevant in systems with high concentrations of nuclei like protons or fluorine. RD occurs when transverse bulk magnetization from the sample, following a radio frequency pulse, induces an electromagnetic field (emf) in the receiver coil of the NMR spectrometer. This generates an oscillating current and a non-linear induced transverse magnetic field which returns the spin system to equilibrium faster than other mechanisms of relaxation. RD can result in line broadening and measurement of a shorter spin–lattice relaxation time (
=== Testing === The American Heart Association recommends testing cholesterol every four to six years for people aged 20 years or older. A separate set of American Heart Association guidelines issued in 2013 indicates that people taking statin medications should have their cholesterol tested 4–12 weeks after their first dose and then every 3–12 months thereafter. For men ages 45 to 65 and women ages 55 to 65, a cholesterol test should be performed every one to two years, and an annual test should be performed for seniors over the age of 65. After 12 hours of fasting, a blood sample is taken by a healthcare professional from an arm vein to measure a lipid profile for a) total cholesterol, b) HDL cholesterol, c) LDL cholesterol, and d) triglycerides. Results may be expressed as "calculated", indicating a calculation of total cholesterol, HDL, and triglycerides. Cholesterol is tested to determine for "normal" or "desirable" levels if a person has a total cholesterol of 5.2 mmol/L or less (200 mg/dL), an HDL value of more than 1 mmol/L (40 mg/dL, "the higher, the better"), an LDL value of less than 2.6 mmol/L (100 mg/dL), and a triglycerides level of less than 1.7 mmol/L (150 mg/dL). Blood cholesterol in people with lifestyle, aging, or cardiovascular risk factors, such as diabetes mellitus, hypertension, family history of coronary artery disease, or angina, are evaluated at different levels.
Sources: en.wikipedia.org
In humans, dominant negative mutations have been implicated in cancer (e.g., mutations in genes p53, ATM, CEBPA, and PPARgamma). Marfan syndrome is caused by mutations in the FBN1 gene, located on chromosome 15, which encodes fibrillin-1, a glycoprotein component of the extracellular matrix. Marfan syndrome is also an example of dominant negative mutation and haploinsufficiency. Lethal mutations result in rapid organismal death when occurring during development and cause significant reductions of life expectancy for developed organisms. An example of a disease that is caused by a dominant lethal mutation is Huntington's disease. Null mutations, also known as amorphic mutations, are a form of loss-of-function mutations that completely prohibit the gene's function. The mutation leads to a complete loss of operation at the phenotypic level, also causing no gene product to be formed. Atopic eczema and dermatitis syndrome are common diseases caused by a null mutation of the gene that activates filaggrin. Suppressor mutations are a type of mutation that causes the double mutation to appear normally. In suppressor mutations the phenotypic activity of a different mutation is completely suppressed, thus causing the double mutation to look normal. There are two types of suppressor mutations: intragenic and extragenic. Intragenic mutations occur in the gene where the first mutation occurs, while extragenic mutations occur in the gene that interacts with the product of the first mutation. A common disease that results from this type of mutation is Alzheimer's disease.
== Company structure == Metrohm is a stock corporation headquartered in Herisau, Switzerland. It is owned by the Metrohm Foundation, which ensures the company's independence. Metrohm is present in around 80 countries through subsidiaries or distribution partners. Amongst others, Metrohm holds the following specialized development and production sites:
Jobe Watson (born 8 February 1985) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Watson, the son of three-time Essendon premiership champion Tim Watson, was drafted by Essendon under the father–son rule in the 2002 national draft, and went on to become one of the best midfielders of the modern era. A dual All-Australian and three-time Crichton Medallist, he captained Essendon from 2010 to early 2016, and was the face of the Essendon playing group during the most turbulent period in the club's history. Watson was one of thirty-four players suspended as part of the Essendon Football Club supplements saga for using the banned performance-enhancing substance Thymosin beta-4 during the 2012 AFL season. He originally won that season's Brownlow Medal as the league's best and fairest player, but was later ruled ineligible in 2016 as a result of the suspension and subsequently handed back the medal. Watson was suspended for the entire 2016 AFL season, before returning the following year; he then played for one more season before retiring. Watson is currently an AFL commentator for the Seven Network, following in the footsteps of his father Tim.
In 2012, newly elected President Enrique Peña Nieto, from the PRI, emphasized that he did not support the involvement of armed American agents in Mexico and was only interested in training Mexican forces in counter-insurgency tactics. At the start of his term, Peña Nieto promised to de-escalate the conflict, focusing on lowering criminal violence rates, as opposed to the previous policy of attacking drug-trafficking organizations by arresting or killing the cartel leaders and intercepting their shipments. His administration's security policy was shaped by Miguel Ángel Osorio Chong (Secretary of the Interior), Jesús Murillo Karam (Attorney General), and Salvador Cienfuegos (National Defense). In the first 14 months of his administration, between December 2012 and January 2014, 23,640 people died in the conflict. During 2012 and 2013, Mexico saw the rise of grupos de autodefensa comunitaria, vigilante self-defense groups in rural communities that took up arms against criminal groups that wanted to impose dominance in their towns, entering a new phase in the Mexican drug war. This strategy, encouraged by Óscar Naranjo, one of Peña Nieto's security advisors, crumbled when autodefensas began having internal struggles and disagreements with the government, as well as infiltration and co-optation by organized crime, causing Peña Nieto's administration to distance from them.
The mostly studied system is yttrium (Y) fractionation between the phosphate monazite and the silicates garnet and xenotime. All three minerals preferentially fractionate Y, yet they form and break down at different stages of metamorphism. Xenotime has the highest fractionating power, then garnet and then monazite. In a simplified case of a clockwise P-T path involving garnet and monazite, garnet grows along a prograde path with Y continuously being incorporated, thus the Y content in monazite formed at this stage (prograde) should decrease progressively with higher grade. However, as temperature increases to a certain point, partial melting (anatectic) of monazite occurs around its rim, releasing Y into the melts. As the system later cools and melt crystallizes, regrown monazite will have higher Y content. Partial melting usually happens during peak metamorphism (the highest temperature in a P-T path), but age and chemical information during this stage are not recorded since the monazite is melting. However, the ages of last prograde growth rim (lowest Y) and the first post-anatectic growth rim (highest Y) usually bracket the time of partial melting. Another scenario involves the formation or breakdown of garnet, influencing the Y and HREE (heavy rare earth elements) content in the environment, thus the content of growing monazite. Basically, monazites grown before garnet formation have a higher Y and HREE content than those formed during or after garnet formation.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.